Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 1 for:    PSOC 2301
Previous Study | Return to List | Next Study

Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Fred Hutchinson Cancer Research Center
ClinicalTrials.gov Identifier:
NCT00476047
First received: May 17, 2007
Last updated: March 3, 2014
Last verified: March 2014

May 17, 2007
March 3, 2014
February 2007
March 2017   (final data collection date for primary outcome measure)
  • Probability of PFS [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Change in residual disease [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    Assessed by CD5, CD19, Kappa, Lambda, and CD20 levels by flow cytometry, PCR, and fluorescence in situ hybridization (FISH) in blood or bone marrow samples.
  • Change in residual disease [ Time Frame: Over 2 years ] [ Designated as safety issue: No ]
    Assessed by CD5, CD19, Kappa, Lambda, and CD20 levels by flow cytometry, PCR, and FISH in blood or bone marrow samples.
  • Change in residual disease [ Time Frame: Over 3 years ] [ Designated as safety issue: No ]
    Assessed by CD5, CD19, Kappa, Lambda, and CD20 levels by flow cytometry, PCR, and FISH in blood or bone marrow samples.
  • Change in residual disease [ Time Frame: Annually for up to approximately 5 ] [ Designated as safety issue: No ]
    Assessed by CD5, CD19, Kappa, Lambda, and CD20 levels by flow cytometry, PCR, and FISH in blood or bone marrow samples.
Estimate the progression-free survival at 2 years after completing 6 cycles of Fludarabine and Rituximab followed by 131 I-Tositumomab (Bexxar) [ Time Frame: 2 years ]
Complete list of historical versions of study NCT00476047 on ClinicalTrials.gov Archive Site
Rate of grade 4 hematologic toxicity as defined by National Institutes of Health (NIH) Common Toxicity Criteria (CTC) v 3.0 [ Time Frame: Up to 3 months post-treatment ] [ Designated as safety issue: Yes ]
  • To eliminate residual disease (documented by flow cytometry or PCR) using 131 I-Tositumomab (Bexxar) in patients who have achieved a complete response to 6 cycles of Fludarabine and Rituximab
  • To assess response rates in those patients who did not achieve a complete response after 6 cycles of Fludarabine and Rituximab
  • Evaluate the toxicities of Fludarabine and Rituximab followed by 131 I-Tositumomab (Bexxar) in patients with newly diagnosed CLL or SLL.
Not Provided
Not Provided
 
Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission
A Study of 131I-Tositumomab (Bexxar®) Consolidation in Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission

This phase II trial studies how well tositumomab and iodine I 131 tositumomab works in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in first remission. Monoclonal antibodies, such as tositumomab and iodine I 131 tositumomab, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer cancer-killing substances to them

PRIMARY OBJECTIVES:

I. To estimate the progression-free survival (PFS) at 2 years following administration of 131I-tositumomab (tositumomab and iodine I 131 tositumomab) in patients with CLL/SLL who achieve a complete response (CR) or partial response (PR) with prior therapy.

II. To improve the response rate by administering 131I-tositumomab to patients who have achieved a PR not a CR after any prior therapy.

III. To eliminate residual disease (documented by flow cytometry or polymerase chain reaction [PCR]) using 131I-tositumomab in patients who have achieved a CR after any prior therapy.

SECONDARY OBJECTIVES:

I. To evaluate the toxicities of 131I-tositumomab in 1st remission patients with previously treated CLL/SLL.

OUTLINE:

Patients receive tositumomab and iodine I 131 tositumomab intravenously (IV) over 90 minutes on day 0 and then again 7-14 days later over 30-60 minutes.

After completion of study treatment, patients are followed up weekly for 3 months, every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

Interventional
Phase 2
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • B-cell Chronic Lymphocytic Leukemia
  • Recurrent Small Lymphocytic Lymphoma
  • Refractory Chronic Lymphocytic Leukemia
  • Radiation: tositumomab and iodine I 131 tositumomab
    Give IV
    Other Names:
    • Bexxar
    • Bexxar therapeutic regimen
  • Other: laboratory biomarker analysis
    Correlative studies
Experimental: Treatment (monoclonal antibody therapy)
Patients receive tositumomab and iodine I 131 tositumomab IV over 90 minutes on day 0 and then again 7-14 days later over 30-60 minutes.
Interventions:
  • Radiation: tositumomab and iodine I 131 tositumomab
  • Other: laboratory biomarker analysis
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
30
Not Provided
March 2017   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with a diagnosis of cluster of differentiation (CD)20+ CLL/SLL; prior to the first treatment patients with CLL must have been either Rai stage III/IV disease or Rai stage I/II with evidence of disease activity as defined by the National Cancer Institute (NCI) 1996 guidelines, and patients with SLL must have been Stage III or IV per Ann Arbor staging system
  • Patient has received prior therapy and is in 1st remission with a partial or complete response to treatment
  • Patients must have no more than 25% of the intratrabecular marrow space involved by leukemia in bone marrow biopsy specimens as assessed microscopically after completion of treatment; bilateral posterior iliac crest core biopsies are required if the percentage of intratrabecular space involved exceeds 10% on a unilateral biopsy; the mean of bilateral biopsies must be no more than 25%
  • Patient must have consented to participate in the study and signed and dated an appropriate institutional review board (IRB)-approved consent form that conforms to federal and institutional guidelines
  • Patient must have a Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 (0 = fully active, able to carry on all pre-disease performance without restriction; 1 = restricted in physically strenuous activity but ambulatory and ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = ambulatory and capable of all self-care but unable to carry out any work activities and is up and about more than 50% of waking hours)
  • Patient must have an anticipated survival of at least 3 months
  • Granulocytes >= 1,500/uL within 14 days of planned dosimetric infusion
  • Platelets >= 100,000/uL within 14 days of planned dosimetric infusion
  • White blood count =< 20,000/mm^3
  • Serum creatinine < 2 times upper limit of normal
  • Total bilirubin < 2 times upper limit of normal
  • Aspartate aminotransferase (AST) < 5 times upper limit of normal
  • Males and females must agree to use a contraceptive method from enrollment to 6 months after receiving I-131 labeled tositumomab

Exclusion Criteria:

  • Patients who have received prior radiolabeled antibody
  • Patients with active hemolysis
  • Patients must not require sustained transfusion support of blood products
  • Patients in 2nd remission or beyond
  • Patients who have undergone treatment with either stem cell or bone marrow transplant
  • Patients with active obstructive hydronephrosis
  • Patients with evidence of any significant systemic illness, active Hepatitis B infection or other active infection at the time of study entry
  • Patients with New York Heart Association class III or IV heart disease or other serious illness that would preclude evaluation
  • Patients with known human immunodeficiency virus (HIV) infection
  • Patients who are pregnant or nursing
  • Patients with prior malignancy other than CLL/SLL, except for adequately treated skin cancer (basal cell or squamous cell carcinoma), in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years unless approved by the principal investigator (PI)
  • Patients with active brain or leptomeningeal involvement by malignancy
  • Patients who have, in the opinion of the investigator, other medical, social, or psychosocial factors that may negatively impact compliance or their safety by participation in this study
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00476047
PSOC 2301, NCI-2011-01311
No
Fred Hutchinson Cancer Research Center
Fred Hutchinson Cancer Research Center
National Cancer Institute (NCI)
Principal Investigator: John Pagel Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Fred Hutchinson Cancer Research Center
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP